Germline genetic testing for hereditary breast and ovarian cancer (HBOC) enables targeted treatment and risk management interventions for women who carry pathogenic or likely pathogenic (P/LP) variants in a cancer predisposition gene, such as BRCA1, BRCA2 or PALB2. This evidence concerns the gene BRCA2 and cancer.